Table 1.
Demographic and clinical factors of matched individuals with SARS-CoV-2 infection by monoclonal antibody therapy status, OptumLabs’ deidentified administrative claims
| Variable | MAb therapy matched group n (%) |
Standard of care matched comparison group n (%) |
P value |
| n | 3798 | 3798 | |
| Demographics | |||
| Age (mean (SD)) | 60.5 (13.4) | 60.3 (13.3) | 0.43 |
| Gender (male) | 1911 (50.3) | 1871 (49.3) | 0.36 |
| Location | |||
| Urban | 1298 (34.2) | 1288 (33.9) | 0.81 |
| Suburban | 1366 (36.0) | 1455 (38.3) | 0.035* |
| Rural | 1134 (29.9) | 1055 (27.8) | 0.045* |
| Census region | |||
| Northeast | 333 (8.8) | 380 (10.0) | 0.064 |
| Midwest | 760 (20.0) | 679 (17.9) | 0.018* |
| South | 2153 (56.7) | 2221 (58.5) | 0.11 |
| West | 552 (14.5) | 518 (13.6) | 0.26 |
| Business line | |||
| Commercial | 2788 (73.4) | 2764 (72.8) | 0.53 |
| Medicare | 1015 (26.7) | 1037 (27.3) | 0.57 |
| MAb eligibility criteria | |||
| Age ≥65 | 1380 (36.3) | 1380 (36.3) | 1.0 |
| BMI ≥35 | 758 (20.0) | 657 (17.3) | 0.0029* |
| Type 1 diabetes | 1485 (39.1) | 1473 (38.8) | 0.78 |
| Type 2 diabetes | 170 (4.5) | 144 (3.8) | 0.13 |
| Chronic kidney disease | 440 (11.6) | 433 (11.4) | 0.80 |
| Immunosuppressive disease | 2963 (78.0) | 2886 (76.0) | 0.036* |
| Receiving immunosuppressive treatment | 353 (9.3) | 330 (8.7) | 0.36 |
| Age ≥55 and at least one of the following: | 1183 (31.1) | 1196 (31.5) | 0.75 |
| Heart disease | 375 (9.9) | 336 (8.8) | 0.12 |
| Hypertension | 2713 (71.4) | 2787 (73.4) | 0.058 |
| COPD | 1062 (28.0) | 1046 (27.5) | 0.68 |
| Other chronic respiratory disease | 146 (3.8) | 121 (3.2) | 0.12 |
| Elixhauser Comorbidity Index | |||
| Mortality score (mean (SD)) | 3.3 (6.4) | 3.1 (6.4) | 0.32 |
| Readmission score (mean (SD)) | 11.8 (14.6) | 10.7 (14.6) | 0.0011* |
| Claims-derived variables | |||
| Primary Care Provider (PCP) visits in 6 months prior to diagnosis (mean number of visits (SD)) | 3.1 (4.2) | 2.9 (4.4) | 0.093 |
| Nephrologist visits in 6 months prior to diagnosis (mean number of visits (SD)) | 0.1 (0.9) | 0.1 (0.8) | 0.96 |
| Cardiologist visits in 6 months prior to diagnosis (mean number of visits (SD)) | 0.4 (1.3) | 0.4 (1.5) | 0.38 |
| Inpatient hospital days in 6 months prior to diagnosis (mean number of days (SD)) | 0.3 (2.9) | 0.3 (2.6) | 0.88 |
| Claims-derived variables | |||
| Bamlanivimab | 2851 (75.1%) | ||
| Bamlanivimab-etesevimab | 353 (9.3%) | ||
| REGN-COV2 | 594 (15.6%) | ||
| Median days to treatment (IQR) | 1 (3) | ||
*Difference when compared with treatment group is statistically significant (p<0.05).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; MAb, monoclonal antibody.